Amgen To Acquire Privately Held Teneobio For $900 Million In Cash With Future Contingent Milestone Payments
Amgen To Acquire Privately Held Teneobio For $900 Million In Cash With Future Contingent Milestone Payments Amgen and Teneobio today announced an agreement under which Amgen will acquire Teneobio, a privately held, clinical stage biotechnology company developing a new class of biologics called Human Heavy-Chain Antibodies. Under the terms of the agreement, Amgen will acquire all outstanding shares of Teneobio at closing in exchange for a $900 million upfront cash payment, as well as future contingent milestone payments … Amgen (NASDAQ: AMGN) and Teneobio today announced an agreement under...
Source: investingnews.com